Martinez-Forero Iván, Pelaez Antonio, Villoslada Pablo
University of Navarra, Center for Applied Medical Research (CIMA), Department of Neuroscience, Neuroimmunology Lab 2.05, 31008 Pamplona, Spain.
Expert Opin Pharmacother. 2008 Dec;9(17):3053-67. doi: 10.1517/14656560802515553.
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system that affects young adults and provokes severe disability, imposing a high health and social burden. Current therapies for MS include interferon-beta, glatiramer acetate, natalizumab and chemotherapy. These therapies decrease the number of relapses and partially prevent disability accumulation. However, their efficacy is only moderate, they have common adverse effects and impose a high cost to health systems. The identification of biomarkers will allow responders and non-responders to therapy to be identified, increasing the efficacy and adherence to therapy, and the pharmaco-economic profile of theses drugs.
In this review we examine the pharmacogenetic studies that have evaluated the clinical response to interferon-beta, and to a lesser extent, glatiramer acetate and natalizumab. Finally, we discuss how systems biology can be used to integrate biological and clinical data in order to develop personalized medicine for MS.
多发性硬化症（MS）是一种中枢神经系统炎症性疾病，影响年轻人并导致严重残疾，带来高昂的健康和社会负担。目前用于治疗MS的方法包括β-干扰素、醋酸格拉替雷、那他珠单抗和化疗。这些疗法可减少复发次数并部分预防残疾累积。然而，它们的疗效仅为中等，存在常见的不良反应，且给卫生系统带来高昂成本。生物标志物的识别将有助于区分治疗的反应者和无反应者，提高治疗效果和依从性，并改善这些药物的药物经济学状况。
在本综述中，我们考察了评估对β-干扰素临床反应的药物遗传学研究，以及对醋酸格拉替雷和那他珠单抗临床反应的较少研究。最后，我们讨论了如何利用系统生物学整合生物学和临床数据，以便为MS开发个性化药物。
